Lung function and peak oxygen uptake in chronic obstructive pulmonary disease phenotypes with and without emphysema

Øystein Rasch-Halvorsen, Erlend Hassel, Ben M. Brumpton, Haldor Jenssen, Martijn A. Spruit, Arnulf Langhammer, Sigurd Steinshamn

1 Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
2 Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
3 Norwegian Armed Forces Occupational Health Service, Trondheim, Norway
4 K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, University of Oslo, Oslo, Norway
5 MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
6 Telemark Heart Lung and Blood Institute, Skien, Norway
7 Department of Research and Development, CIRO, Herm, The Netherlands
8 Department of Respiratory Medicine, Maastricht University Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands
9 REVAL–Rehabilitation Research Center, BIOMED–Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium
10 Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

These authors contributed equally to this work.

Abstract

Previous studies of associations of forced expiratory lung volume in one second (FEV$_1$) with peak oxygen uptake (VO$_{2peak}$) in chronic obstructive pulmonary disease (COPD) have not taken sex, age and height related variance of dynamic lung volumes into account. Nor have such demographic spread of spirometric measures been considered in studies comparing VO$_{2peak}$ between COPD phenotypes characterized by degree of emphysema. We aimed to assess the association of FEV$_{1Z}$-score with VO$_{2peak}$ in COPD (n = 186) and investigate whether this association differs between emphysema (E-COPD) and non-emphysema (NE-COPD) phenotypes. Corresponding assessments using standardized percent predicted FEV$_1$ (ppFEV$_1$) were performed for comparison. Additionally, phenotype related differences in VO$_{2peak}$ were compared using FEV$_{1Z}$-score and ppFEV$_1$ as alternative expressions of FEV$_1$. E-COPD and NE-COPD were defined by transfer factor of the lung for carbon monoxide below and above lower limits of normal (LLN), respectively. The associations were assessed in linear regression models. One unit reduction in FEV$_{1Z}$-score was associated with 1.9 (95% CI 1.4, 2.5) ml/kg/min lower VO$_{2peak}$. In stratified analyses, corresponding estimates were 2.2 (95% CI 1.4, 2.9) and 1.2 (95% CI 0.2, 2.2) ml/kg/min lower VO$_{2peak}$ in E-COPD and NE-COPD, respectively. The association did not differ statistically by COPD phenotype (p-value for interaction = 0.153). Similar estimates were obtained in analyses using standardized ppFEV$_1$. Compared to NE-COPD, VO$_{2peak}$ was 2.2 (95% CI 0.8, 3.6) and 2.1 (95% CI 0.8, 3.5) ml/kg/min lower in E-COPD when adjusted for FEV$_{1Z}$-score and ppFEV$_1$, respectively. In COPD, FEV$_{1Z}$-score is positively associated with VO$_{2peak}$. This association...
was stronger in E-COPD but did not differ statistically by phenotype. Both the association of FEV₁ with VO₂peak and the difference in VO₂peak comparing COPD phenotypes seems independent of sex, age and height related variance in FEV₁. Mechanisms leading to reduction in FEV₁ may contribute to lower VO₂peak in E-COPD.

Introduction

In current strategic documents provided by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the post-bronchodilator ratio of forced expiratory lung volume in one second/forced vital capacity (FEV₁/FVC) is the key diagnostic variable defining chronic obstructive pulmonary disease (COPD) [1]. Reduced FEV₁ denotes the severity of airway obstruction and may reflect the pathophysiological mechanism of expiratory flow limitation (EFL) at rest or during exercise, characteristic of this disease [2].

Dynamic hyperinflation (DH), inflicting restrictive constraints on tidal volume expansion, is a functional consequence of EFL [3] and associated with dyspnea and exercise limitation in COPD [4]. Exercise intolerance from dyspnea on exertion is a major manifestation of COPD leading to physical inactivity, deconditioning and reduced exercise capacity [5]. Assessed by cardiopulmonary exercise testing (CPET), peak oxygen uptake (VO₂peak) is a direct measure of exercise capacity and reduced values are associated with increased mortality in COPD [6].

Although integrated in the concept of ventilatory limitation to exercise, variables of airway obstruction and exercise capacity are not strongly associated in COPD [7–9]. However, previous studies have not adequately taken sex, age and height related variance of dynamic lung volumes into account when reporting associations of FEV₁ with VO₂peak among those with COPD. Furthermore, the specificity of the diagnostic criterion of airway obstruction, when defined by the fixed ratio of post-bronchodilator FEV₁/FVC less than 0.70, is age dependent and may lead to over-diagnosis of COPD in an older population [10–12]. In contrast to percent predicted FEV₁ (ppFEV₁), and the fixed ratio of FEV₁/FVC, Z-scores of these measures provide spirometric expressions that are comparable independent of sex, age and height. Reference equations for the calculation of Z-scores of dynamic lung volumes are readily available [13], and both the American Thoracic Society (ATS) and the European Respiratory Society (ERS) have endorsed defining the lower limit of normal (LLN) of lung function measures by the fifth percentile (z-score = -1.645) [14].

COPD is recognized as a heterogeneous disease and different phenotypes have been proposed [15]. In patients with predominantly emphysema (E-COPD), destruction of the pulmonary parenchyma leads to increased compliance from loss of elastic recoil pressure predisposing dynamic compression of the airways. The non-emphysema (NE-COPD) phenotype is characterized by airway inflammation with intrinsic caliber reduction and increased airflow resistance. These two phenotypes represent pathophysiological diversity in COPD highlighting mechanisms contributing to reduced FEV₁ and expiratory flow limitation.

The transfer factor of the lung for carbon monoxide (T₁CO) has been used to differentiate E-COPD from NE-COPD [14]. Patients with reduced T₁CO have been shown to have lower VO₂peak than patients with more preserved T₁CO when compared at similar ppFEV₁ [4]. It is unknown whether this difference in VO₂peak is related to normalization of FEV₁ by ppFEV₁, and/or whether the association of FEV₁ with VO₂peak is stronger in E-COPD than in NE-COPD. Alternatively, mechanisms unrelated to FEV₁ may explain the difference in exercise capacity comparing these COPD phenotypes.
Classification of patients by COPD phenotypes should be related to differences in clinically important outcomes [16]. New knowledge on associations between major diagnostic and prognostic measures in readily identifiable phenotypes of this multifaceted disease is likely to be of scientific and clinical value. We aimed to assess the association of FEV\textsubscript{1}Z-score with VO\textsubscript{2peak} in COPD and investigate whether this association differs comparing phenotypes with and without emphysema. Additionally, we explored the potential influence of sex, age and height related variance in FEV\textsubscript{1} on both the association of FEV\textsubscript{1} with VO\textsubscript{2peak} and on the difference in VO\textsubscript{2peak} between E-COPD and NE-COPD.

Materials and methods

Study population

We assessed patients referred for evaluation with pulmonary function tests (PFT) and CPET due to exercise intolerance at a private specialist clinic in Norway (Telemark Heart Lung and Blood Institute) between May 1999 and November 2014. The clinical database was accessed in the time period between the fifteenth of July and the thirtieth of August 2015. Patients with COPD (n = 301) were included.

In this study, the diagnostic criterion of airway obstruction in COPD was defined by the post-bronchodilator FEV\textsubscript{1}/FVC less than LLN. E-COPD and NE-COPD phenotypes were defined by T\textsubscript{L}CO below and above LLN, respectively [14]. LLN was defined as the fifth percentile (z-score = -1.645). Predicted values and Z-scores of dynamic lung volumes and lung diffusing capacity measures were calculated using the Global Lung Function Initiative (GLI) software [17, 18].

Patients > 80 years of age (n = 6) were excluded due to having an age above the valid range of the GLI 2017 reference values for T\textsubscript{L}CO. Patients ≤ 45 years of age (n = 28) were excluded due to low prevalence of COPD in this age group. We excluded 33 patients with a clinical diagnosis of asthma. In order to ensure uniform modality of exercise testing, 13 patients were excluded due to having performed the CPET on a treadmill. Furthermore, 19 patients were excluded because of termination of CPET due to chest pain and electrocardiogram (ECG) changes suggestive of myocardial ischemia (n = 2), arrhythmia or high blood pressure (n = 9), leg/knee or hip-pain (n = 4), caution due to known aortic valve disease or aortic aneurysm (n = 2), inadequate cycling technique (n = 1) or lack of motivation (n = 1). We also excluded 11 patients who performed PFT and CPET more than 3 months apart.

Three patients were excluded due to missing values on T\textsubscript{L}CO and two patients due to missing values on smoking status. After exclusions, 186 patients remained in the statistical analyses.

Pulmonary function tests

Spirometry and lung diffusing capacity (Vmax Legacy/Spectra 229; SensorMedics) were tested on separate visits, but no more than 3 months prior to CPET (exclusion criterion). The procedures adhered to recommendations provided by the American Thoracic Society/European Respiratory Society guidelines [19, 20].

Cardiopulmonary exercise test

An incremental exercise test was performed on a cycle ergometer (ER900; Ergoline). The work rate was increased by 5–25 W/minute on an individualized basis aiming for test termination after 8–12 minutes. The patients reported the dominating symptom limiting further exercise as dyspnea, leg discomfort/fatigue or other. The reasons for test termination in the latter category included pain in lower extremities (n = 9), vertigo (n = 4) and attainment of estimated maximal heart rate (n = 1).
Breath by breath measurements (Vmax Legacy/Spectra 229; SensorMedics) of oxygen uptake (VO\textsubscript{2}) and carbon dioxide output (VCO\textsubscript{2}) were averaged over 20 seconds. The highest value of VO\textsubscript{2} was normalized by bodyweight and termed VO\textsubscript{2peak}.

Pulse oximetry (S\textsubscript{p}O\textsubscript{2}) was measured continuously from rest to test termination using a finger probe (Model 340; Palco Labs/8600; Nonin). The minimum value was termed S\textsubscript{p}O\textsubscript{2min}.

Maximal voluntary ventilation (MVV) was estimated by FEV\textsubscript{1} x 40 \cite{21}. Ventilatory reserve (VR) was calculated as VR = 1 –Minute ventilation at peak exercise (VE\textsubscript{peak})/MVV \cite{22}. Maximal heart rate (HR\textsubscript{max}) was estimated by 220 – age. Heart rate reserve (HRR) was calculated as HRR = 1 –Heart rate at peak exercise (HR\textsubscript{peak})/HR\textsubscript{max} \cite{22}.

### Statistical analyses

Descriptive statistics, calculated as mean and standard deviation (SD) or number of observations and percentages, are reported for both the total sample and the sample stratified by COPD phenotype. Lung function and exercise variables were compared between patients with E-COPD and NE-COPD using independent samples t-tests.

The association of FEV\textsubscript{1Z-score} with VO\textsubscript{2peak} was investigated in linear regression models. In a total sample model, VO\textsubscript{2peak} was regressed on FEV\textsubscript{1Z-score} and COPD phenotype. Body mass index (BMI), smoking status (former or current), beta-blocker and bronchodilator treatment (both dichotomous), were considered potential confounders. In separate models adjustments were also made for sex and age due to known strong associations with VO\textsubscript{2peak}. An interaction term (FEV\textsubscript{1Z-score} x COPD phenotype) was included in a separate analysis to investigate effect modification of COPD phenotype on the association of FEV\textsubscript{1Z-score} with VO\textsubscript{2peak}. Due to potential lack of power in the interaction analysis, the associations of FEV\textsubscript{1Z-score} with VO\textsubscript{2peak} were also estimated in analyses stratified by COPD phenotype. Corresponding analyses with standardized ppFEV\textsubscript{1}, calculated as (observed value–sample mean)/SD, were performed for comparison. Regression coefficients (β) with 95% confidence intervals (CI) are reported.

Linear regression models were also used to investigate whether the difference in VO\textsubscript{2peak} between E-COPD and NE-COPD is influenced by sex, age and height related variance in FEV\textsubscript{1}. VO\textsubscript{2peak} was regressed on COPD phenotype, FEV\textsubscript{1Z-score} and ppFEV\textsubscript{1} in separate models adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment.

The potential influence of effort dependent underestimation of maximal exercise capacity from VO\textsubscript{2peak} was evaluated in a sensitivity analysis including only those with reduced VR and/or HRR. VO\textsubscript{2peak} was regressed on FEV\textsubscript{1Z-score} and COPD phenotype with adjustment for age, sex, BMI, smoking status, beta-blocker and bronchodilator treatment.

Residual plots were inspected in all models, and no violations of the assumptions of linear regression were uncovered. Statistical analyses were performed with IBM SPSS Statistics Version 25 (IBM Corp., Armonk, NY, USA).

### Ethics approval

The Regional Committee for Medical and Health Research Ethics approved this retrospective study and the use of anonymous data without informed consent (REC-Central 2012/673).

### Results

#### Clinical characteristics and PFT measures

The majority of patients were men, in both the total cohort (65%) and in subgroups stratified by COPD phenotype (63% vs. 67% in E-COPD and NE-COPD, respectively). Mean values of age, BMI and SpO\textsubscript{2} at rest were similar in both phenotypes (63.9 vs. 60.4 years, 25.6 vs. 26.7
kg/m² and 95.1 vs. 96.0% in E-COPD and NE-COPD, respectively). All patients were former or current smokers with similar proportions in both phenotypes (current smokers; 51% vs. 49% in E-COPD and NE-COPD, respectively). The majority of patients did not receive any beta-blocker (67% vs. 76% in E-COPD and NE-COPD, respectively), but had ongoing bronchodilator treatment (73% vs. 53% in E-COPD and NE-COPD, respectively) (Table 1).

Compared to patients with NE-COPD, patients with E-COPD had lower FEV₁Z-score (difference 0.69, 95% CI 0.36, 1.02, p < 0.001), lower FVCZ-score (difference 0.42, 95% CI 0.05, 0.79, p = 0.028), lower (FEV₁/FVC)Z-score (difference 0.62, 95% CI 0.38, 0.86, p < 0.001), lower KCOZ-score (difference 1.74, 95% CI 1.40, 2.07, p < 0.001), lower VAZ-score (difference 0.91, 95% CI 0.56, 1.27, p < 0.001) and, by definition, lower T₁COZ-score (difference 2.41, 95% CI 2.14, 2.68, p < 0.001) (Table 1).

**CPET measures**

The majority of patients reported test termination due to dyspnea in both phenotypes, but the proportion was higher in E-COPD than in NE-COPD (67 vs. 52%). The proportion reporting test termination due to leg fatigue was lower in E-COPD than in NE-COPD (26 vs. 40%) (Table 2).

### Table 1. Clinical characteristics and pulmonary function test measures in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD phenotypes.

|                          | Total  (n = 186) | E-COPD (n = 101) | NE-COPD (n = 85) | p-value |
|--------------------------|-----------------|-----------------|-----------------|---------|
| Men/women                | 121/65 (65)/65 (35) | 64 (63)/37 (37) | 57 (67)/28 (33) |         |
| Age (years)              | 62.3 ± 8.9       | 63.9 ± 9.3      | 60.4 ± 8.0      |         |
| BMI (kg/m²)              | 26.1 ± 3.6       | 25.6 ± 3.7      | 26.7 ± 3.4      |         |
| SpO₂ (%)                 | 95.5 ± 2.0       | 95.1 ± 2.2      | 96.0 ± 1.6      |         |
| Former/current smokers   | 92 (49)/94 (51)  | 49 (49)/52 (51) | 43 (51)/42 (49) |         |
| Beta-blocker             | 53 (28)          | 33 (33)         | 45 (53)         |         |
| Bronchodilator           | 119 (64)         | 74 (73)         | 45 (53)         |         |
| FEV₁ (L)                 | 2.06 ± 0.77      | 1.82 ± 0.73     | 2.33 ± 0.73     | < 0.001 |
| FEV₁Z-score              | -2.16 ± 1.21     | -2.48 ± 1.24    | -1.78 ± 1.06    |         |
| ppFEV₁ (%)               | 65.8 ± 19.8      | 59.8 ± 20.7     | 72.8 ± 16.2     |         |
| FVC (L)                  | 3.77 ± 1.10      | 3.58 ± 1.02     | 4.00 ± 1.15     |         |
| FVCZ-score               | 93.4 ± 19.4      | 90.5 ± 20.2     | 96.8 ± 17.8     | 0.028   |
| ppFVC (%)                | -0.45 ± 1.29     | -0.65 ± 1.33    | -0.23 ± 1.21    |         |
| FEV₁/FVC                 | 0.54 ± 0.10      | 0.50 ± 0.11     | 0.58 ± 0.07     |         |
| KCO (mmol/min/kPa/L)     | 6.07 ± 2.05      | 4.80 ± 1.20     | 7.57 ± 1.82     | < 0.001 |
| KCOZ-score               | -1.98 ± 1.54     | -3.08 ± 1.10    | -0.67 ± 0.77    | < 0.001 |
| VA (L)                   | 5.44 ± 1.33      | 5.13 ± 1.22     | 5.82 ± 1.38     |         |
| VAZ-score                | -0.70 ± 1.30     | -1.12 ± 1.29    | -0.21 ± 1.14    | < 0.001 |
| T₁CO (mmol/min/kPa)      | 1.13 ± 0.29      | 0.96 ± 0.23     | 1.32 ± 0.23     |         |
| T₁COZ-score              | -1.47 ± 1.43     | -2.27 ± 1.22    | -0.53 ± 1.05    | < 0.001 |

Values are mean ± standard deviation or number of observations (percentages). COPD—chronic obstructive pulmonary disease, BMI—body mass index, SpO₂—pulse oximetry, FEV₁—forced expiratory lung volume in one second, pp—percent predicted, FVC—forced vital capacity, KCO—diffusion constant for carbon monoxide, VA—alveolar volume, T₁CO—transfer factor of the lung for carbon monoxide.

* n = 181: Emphysema/non-emphysema = 98/83.

https://doi.org/10.1371/journal.pone.0252386.t001
Compared to patients with NE-COPD, patients with E-COPD had lower VO$_2$peak (difference 4.8 ml/kg/min, 95% CI 3.0, 6.5, p < 0.001), lower RER$_{peak}$ (difference 0.04, 95% CI 0.004, 0.08, p = 0.031), higher HRR (difference 6.1%, 95% CI 2.5, 9.6, p = 0.001), lower VE$_{peak}$ (difference 14.8 l/min, 95% CI 7.8, 21.9, p < 0.001), lower VR (difference 5.5%, 95% CI -0.5, 11.5, p = 0.073) and lower SpO$_2$min (difference 1.7%, 95% CI 0.9, 2.6, p < 0.001) (Table 2).

### Table 2. Cardiopulmonary exercise test measures in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD phenotypes.

| Test termination | Total (n = 186) | E-COPD (n = 101) | NE-COPD (n = 85) | p-value |
|------------------|----------------|-----------------|-----------------|---------|
| Dyspnea          | 112 (60)       | 68 (67)         | 44 (52)         |         |
| Leg fatigue      | 60 (32)        | 26 (26)         | 34 (40)         |         |
| Other*           | 14 (8)         | 7 (7)           | 7 (8)           |         |
| VO$_2$peak (ml/kg/min) | 20.9 ± 6.5 | 18.7 ± 5.5 | 23.5 ± 6.6 | < 0.001 |
| RER$_{peak}$     | 1.11 ± 0.13    | 1.09 ± 0.14     | 1.13 ± 0.13     | 0.031   |
| HRR (%)          | 9.9 ± 12.7     | 12.7 ± 12.9     | 6.6 ± 11.6      | 0.001   |
| VE$_{peak}$ (L/min) | 67.9 ± 25.2 | 61.1 ± 22.6 | 76.0 ± 25.9 | < 0.001 |
| MVV (L/min)      | 82.2 ± 30.8    | 72.9 ± 29.1     | 93.3 ± 29.2     |         |
| VR (%)           | 14.5 ± 20.9    | 11.9 ± 23.0     | 17.5 ± 17.7     | 0.073   |
| SpO$_2$min (%)   | 94.3 ± 3.2     | 93.5 ± 3.6      | 95.3 ± 2.2      | < 0.001 |

Values are mean ± standard deviation or number of observations (percentages). COPD–chronic obstructive pulmonary disease, VO$_2$peak–oxygen uptake at peak exercise, RER$_{peak}$–respiratory exchange ratio at peak exercise, HRR–heart rate reserve, VE$_{peak}$–minute ventilation at peak exercise, MVV–maximal voluntary ventilation, VR–ventilatory reserve, SpO$_2$min–minimum value pulse oximetry.

*Pain in lower extremities (n = 9). Vertigo (n = 4). Attainment of estimated maximal heart rate (n = 1).

**n = 185: Emphysema/non-emphysema = 100/85.

***n = 185: Emphysema/non-emphysema = 101/84.

https://doi.org/10.1371/journal.pone.0252386.t002

### Table 3. Associations of FEV$_1$Z-score with VO$_2$peak and effect modification by COPD phenotype

| FEV$_1$Z-score | Model 1* | Model 2* | Model 3* | Model 4* |
|----------------|----------|----------|----------|----------|
| FEV$_1$Z-score | n = 186  | n = 101  | n = 85   |          |
| VO$_2$peak (ml/kg/min) | 1.6 | 0.9, 2.3 | 2.0 | 1.4, 2.6 | 2.1 | 1.5, 2.6 | 1.9 | 1.4, 2.5 |
| E-COPD        | 1.6 | 0.7, 2.4 | 2.0 | 1.3, 2.7 | 2.2 | 1.5, 2.9 | 2.2 | 1.4, 2.9 |
| NE-COPD       | 1.6 | 0.3, 2.9 | 2.0 | 0.9, 3.1 | 1.6 | 0.6, 2.6 | 1.2 | 0.2, 2.2 |

FEV$_1$Z-score–forced expiratory lung volume in one second Z-score, VO$_2$peak–peak oxygen uptake, COPD–chronic obstructive pulmonary disease, β–regression coefficient, CI–confidence interval.

*Crude association.

**Adjusted for sex and age (years).

*Adjusted for sex, age, body mass index (BMI) and smoking status (former, current).

*Adjusted for sex, age, BMI, smoking status, systemic beta-blocker (yes, no) and inhaled bronchodilator (yes, no).

*Adjusted for COPD phenotype in all total sample models.

https://doi.org/10.1371/journal.pone.0252386.t003
Stratified by COPD phenotype, one unit reduction in FEV$_1$Z-score was, on average, associated with 2.2 (95% CI 1.4, 2.9) and 1.2 (95% CI 0.2, 2.2) ml/kg/min lower VO$_{2peak}$ in E-COPD and NE-COPD, respectively after adjustment for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment (Table 3). The association of FEV$_1$Z-score with VO$_{2peak}$ did not differ statistically by phenotype (p-value for interaction = 0.153).

**Associations of standardized ppFEV$_1$ with VO$_{2peak}$ and effect modification by COPD phenotype**

Adjusted for COPD phenotype, sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment, one unit reduction in standardized ppFEV$_1$ (i.e. one SD reduction in ppFEV$_1$) was, on average, associated with 2.5 (95% CI 1.8, 3.2) ml/kg/min lower VO$_{2peak}$ (Table 4). Stratified by COPD phenotype, one unit reduction in standardized ppFEV$_1$ was, on average, associated with 2.7 (95% CI 1.8, 3.6) and 1.6 (95% CI 0.3, 2.9) ml/kg/min lower VO$_{2peak}$ in E-COPD and NE-COPD, respectively after adjustment for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment (Table 4). The association of standardized ppFEV$_1$ with VO$_{2peak}$ did not differ statistically by phenotype (p-value for interaction = 0.220).

**Phenotype related differences in VO$_{2peak}$ between FEV$_1$Z-score and ppFEV$_1$**

Adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment, VO$_{2peak}$ was, on average, 2.2 (95% CI 0.8, 3.6) and 2.1 (95% CI 0.8, 3.5) ml/kg/min lower in E-COPD than in NE-COPD, when comparisons were made at similar FEV$_1$Z-score and ppFEV$_1$, respectively.

**Sensitivity analyses**

In the sensitivity analyses including only those with reduced VR and/or HRR, one unit reduction in FEV$_1$Z-score was, on average, associated with 2.2 (95% CI 1.5, 2.8) ml/kg/min lower VO$_{2peak}$ after adjustment for COPD phenotype, sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment.

Stratified by COPD phenotype, one unit reduction in FEV$_1$Z-score was, on average, associated with 2.5 (95% CI 1.6, 3.4) and 1.3 (95% CI 0.3, 2.3) ml/kg/min lower VO$_{2peak}$ in E-COPD (n = 68) and NE-COPD (n = 66), respectively after adjustment for sex, age, BMI, smoking

|                      | Model 1$^a$ | Model 2$^b$ | Model 3$^c$ | Model 4$^d$ |
|----------------------|------------|------------|------------|------------|
|                      | n          | β          | 95% CI     | β          | 95% CI     | β          | 95% CI     | β          | 95% CI     |
| Total$^e$            | 186        | 2.5        | 1.6, 3.3   | 2.6        | 1.8, 3.3   | 2.7        | 2.0, 3.3   | 2.5        | 1.8, 3.2   |
| E-COPD               | 101        | 2.4        | 1.4, 3.3   | 2.5        | 1.7, 3.3   | 2.7        | 1.9, 3.5   | 2.7        | 1.8, 3.6   |
| NE-COPD              | 85         | 2.6        | 0.9, 4.3   | 2.6        | 1.2, 4.0   | 2.0        | 0.7, 3.3   | 1.6        | 0.3, 2.9   |

ppFEV$_1$ –percent predicted forced expiratory lung volume in one second, VO$_{2peak}$–peak oxygen uptake, COPD–chronic obstructive pulmonary disease, β–regression coefficient, CI–confidence interval.

$^a$Crude association.

$^b$Adjusted for sex and age (years).

$^c$Adjusted for sex, age, body mass index (BMI) and smoking status (former, current).

$^d$Adjusted for sex, age, BMI, smoking status, systemic beta-blocker (yes, no) and inhaled bronchodilator (yes, no).

$^e$Adjusted for COPD phenotype in all total sample models.

https://doi.org/10.1371/journal.pone.0252386.t004
status, beta-blocker and bronchodilator treatment. The association of FEV\textsubscript{1Z-score} with VO\textsubscript{2peak} did not differ statistically by phenotype (p-value for interaction = 0.051).

Adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment, VO\textsubscript{2peak}, was, on average, 2.0 (95% CI 0.3, 3.6) ml/kg/min lower in E-COPD than in NE-COPD, when comparisons were made at similar FEV\textsubscript{1Z-score}.

**Discussion**

In this study we found FEV\textsubscript{1Z-score} to be positively associated with VO\textsubscript{2peak}. This association was stronger in E-COPD than in NE-COPD but did not differ statistically by phenotype. In corresponding analyses with standardized ppFEV\textsubscript{1}, similar estimates were observed. Exercise capacity was lower in E-COPD than in NE-COPD, but the phenotype related differences in VO\textsubscript{2peak} were similar when comparisons were made using FEV\textsubscript{1Z-score} and ppFEV\textsubscript{1}.

Previous studies have reported weak positive associations between measures of dynamic lung volumes and exercise capacity in patients with COPD [8, 9]. Weak positive correlations between FEV\textsubscript{1} and VO\textsubscript{2peak} may be expected in a heterogeneous disease where multiple organ systems and pathophysiological mechanisms interact and contribute in a highly variable manner to exercise limitation in individual patients [23]. However, normalization of FEV\textsubscript{1} by using percent predicted may also weaken the association with VO\textsubscript{2peak}, especially in diverse study populations with regards to sex, age and height. The present study is the first to report the association of FEV\textsubscript{1} with VO\textsubscript{2peak} in COPD using Z-scores of FEV\textsubscript{1}/FVC and FEV\textsubscript{1} to define both the presence of as well as the degree of airway obstruction, respectively. Although, we support the use of Z-scores of dynamic lung volumes in the diagnostic process in COPD, the associations of FEV\textsubscript{1} with VO\textsubscript{2peak} were similar using FEV\textsubscript{1Z-score} and standardized ppFEV\textsubscript{1}. Thus we have no reason to state that Z-scores are preferable over percent predicted regarding the association of FEV\textsubscript{1} with VO\textsubscript{2peak} in COPD. On average, one unit reduction in FEV\textsubscript{1Z-score} was associated with 1.9 ml/min/kg (95% CI 1.4, 2.5) lower VO\textsubscript{2peak}. The minimal clinically important difference in VO\textsubscript{2peak} has not been established in COPD, but we consider this magnitude, representing 9% of the mean VO\textsubscript{2peak} (20.9 ml/kg/min) in this sample, likely to represent variability in functional impairment.

Several studies have reported differences in exercise capacity for any given reduction in ventilatory capacity when comparing patients with COPD phenotypically stratified by degree of emphysema. O’Donnell et al. [4] reported lower VO\textsubscript{2peak} in patients with COPD and reduced T\textsubscript{l}CO (38 ± 8% predicted) compared to patients with similar ppFEV\textsubscript{1} but more preserved T\textsubscript{l}CO (73 ± 4% predicted). Farkhooy et al. [24] found T\textsubscript{l}CO to be an independent predictor of exercise capacity, assessed by peak workload, in patients with varying severity of COPD. Consistent with the results of these studies, we found lower VO\textsubscript{2peak} in patients with E-COPD defined by T\textsubscript{l}CO below LLN. The estimated difference in VO\textsubscript{2peak} comparing E-COPD and NE-COPD was 2.2 (95% CI 0.8, 3.6) and 2.1 (95% CI 0.8, 3.5) ml/kg/min when patients were compared at similar FEV\textsubscript{1Z-score} and ppFEV\textsubscript{1}, respectively. Thus, the difference in exercise capacity comparing these two COPD phenotypes seems independent of sex, age and height related variance in FEV\textsubscript{1}. In fact, lower exercise capacity in E-COPD seems to be conditional on pathophysiological mechanisms unrelated to reduction in ventilatory capacity as estimated from FEV\textsubscript{1}.

In a small study of patients with COPD and moderate to severe emphysema (n = 16), Paoletti et al. [25] compared the ventilatory response to maximal incremental exercise between patients with degree of emphysema above and below 50% as measured by high resolution computed tomography. In the group with over 50% emphysema, there was evidence of more dynamic hyperinflation, higher tidal volume to inspiratory capacity ratio (V\textsubscript{T}/IC), higher end-
tidal partial pressure of CO₂ (\(P_{ET\text{CO}_2}\)) as well as increasing arterial partial pressure of CO₂ (\(P_{a\text{CO}_2}\)) at peak exercise, suggesting greater mechanical constraints and relative hypoventilation in this group. O'Donnell et al. [4] also found more dynamic hyperinflation at lower exercise levels, more rapid attainment of volume constraints and higher degree of exercise induced dyspnea in patients with COPD and lower compared to higher \(T_{1\text{CO}}\). We found both lower VR, suggesting higher ventilatory demand at peak exercise relative to estimated maximal ventilatory capacity, and a higher proportion reporting test termination due to dyspnea in E-COPD compared to NE-COPD. Mechanical ventilatory limitation may therefore be a principal pathophysiological mechanism explaining the difference in exercise capacity between patients with E-COPD and NE-COPD found in our study.

Since lower aerobic capacity in E-COPD seems to be unrelated to ventilatory capacity, we may also hypothesize that greater inclination to mechanical ventilatory limitation is caused by increased ventilatory demand due to more pronounced gas exchange abnormalities and ventilatory inefficiency in E-COPD. Unfortunately, due to technical problems in the initial data extracting process, only peak exercise data were available and measures of ventilatory efficiency were therefore not included in this study. However, Rinaldo et al. [26] recently reported differences in ventilatory efficiency when comparing noninvasive measures between patients with emphysema and non-emphysema COPD phenotypes. The ventilatory equivalents for CO₂ (VE/VCO₂), both nadir and slope below ventilatory compensation point, were higher in emphysema indicating more pronounced ventilatory inefficiency in this phenotype.

Although we did not find strong evidence to support an effect modification of COPD phenotype on the association between \(FEV_{1\text{Z-score}}\) and \(VO_{2\text{peak}}\) (p-value for interaction 0.153), the estimated association was stronger in E-COPD (2.2 ml/kg/min, 95% CI 1.4, 2.9) than in NE-COPD (1.2 ml/kg/min, 95% CI 0.2, 2.2). Therefore, we cannot exclude the possibility that, additionally to being a marker of ventilatory capacity, any reduction in \(FEV_1\) may either impact or reflect gas exchange, ventilation/perfusion (V/Q) heterogeneity and ventilatory efficiency differently depending on COPD phenotype. Interestingly, although not confirmative of such speculation, we did find lower \(S_pO_{2\text{min}}\) in E-COPD compared to NE-COPD. Future studies are warranted and should aim to address underlying pathophysiological mechanisms explaining differences in exercise capacity comparing E-COPD and NE-COPD. In this regard, we believe invasive measures of gas exchange and calculations of dead space ventilation from arterial blood gasses would be beneficial.

Boutou et al. [27] found percent predicted \(T_{1\text{CO}}\) (pp\(T_{1\text{CO}}\)) to be an independent predictor of survival in patients with COPD, and the impact of \(VO_{2\text{peak}}\) on mortality is well known in this disease [6]. By confirming a positive association between phenotype assessment by \(T_{1\text{COZ-score}}\) and \(VO_{2\text{peak}}\), the present study provides additional evidence linking two prognostic measures in COPD. In agreement with previous studies [24–27], we advocate that assessment of \(T_{1\text{CO}}\) should be considered in the evaluation of patients with COPD to add clinical information not inferable from simple spirometric measurements alone. Furthermore, the finding of both lower \(FEV_{1\text{Z-score}}\) and \(VO_{2\text{peak}}\) in patients with E-COPD, coincide with COPD phenotype being a positive modifier of the association between these key variables. We suggest that differentiation between \(T_{1\text{CO}}\) below and above LLN should complement measures of dynamic lung volumes in future studies of exercise capacity in COPD.

A strength of the current study is that we used Z-scores of lung function measures when reporting the association of \(FEV_1\) with \(VO_{2\text{peak}}\). This approach is novel and E-COPD and NE-COPD may be more correctly differentiated by \(T_{1\text{COZ-score}}\) taking sex, age and height related variance into account, than by pp\(T_{1\text{CO}}\). Furthermore, confounding effects of sex and age on the association of \(FEV_{1\text{Z-score}}\) with \(VO_{2\text{peak}}\) are likely to reflect sampling variation, which was explored in a separate model. Additionally, the patients assessed in this study were
referred for evaluation from primary care and may represent patients typically encountered in a specialist clinic for diagnostic or prognostic evaluation of COPD.

This study has limitations. COPD phenotypes were dichotomized into E-COPD and NE-COPD based on $T_{1/C}O$ below and above LLN, respectively. Although the pre-test probability for emphysema is assumed high in this study population consisting of patients with COPD, radiological qualitative and quantitative confirmation by thoracic computed tomography was not available. On the other hand, this is a real life study and assessment of emphysematous component by $T_{1/C}O$ in obstructive lung disease is recommended in clinical practice [14].

The gold standard to assess exercise capacity is direct measurement of $VO_2$ at maximal exercise ($VO_2max$). $VO_2peak$, used in this study, is susceptible to patient effort and may underestimate true $VO_2max$ [28]. Provided that any underestimation of $VO_2max$ from $VO_2peak$ is unrelated to $FEV_{1Z-score}$, only the precision of the estimates should potentially be influenced. In contrast, associations between underestimation of $VO_2max$ from $VO_2peak$ and $FEV_{1Z-score}$ could introduce systematic error and bias the results. We identified 52 patients (E-COPD; n = 33) with both VR above 15% and HRR above 10%, potentially indicative of submaximal effort, i.e. both preserved residual capacity of the ventilatory and cardiac system, respectively [22]. Excluding these patients in the sensitivity analyses did not appreciably influence the estimates.

In this cross sectional study we can only test for associations. The nature of the data does not permit causal inference or definite conclusions on involved pathophysiological mechanisms behind observed results. Therefore, the clinical value of differentiation on COPD phenotype, supported by this study, cannot be extended to suggest specific treatment recommendations in individual patients.

Conclusions

In COPD, $FEV_{1Z-score}$ is positively associated with $VO_2peak$. This association was stronger in E-COPD than in NE-COPD but did not differ statistically by phenotype. Both the association of $FEV_1$ with $VO_2peak$ and the difference in $VO_2peak$ comparing COPD phenotypes seems independent of sex, age and height related variance in $FEV_1$. Mechanisms leading to reduction in $FEV_1$ may contribute to lower $VO_2peak$ in E-COPD. Future studies aiming to address underlying pathophysiological mechanisms of these findings are warranted.

Supporting information

S1 Dataset. Minimal dataset.
(SAV)

Acknowledgments

The authors would like to acknowledge Marina Vang for her contribution as a research assistant in the initial data extraction process.

Author Contributions

Conceptualization: Øystein Rasch-Halvorsen, Erlend Hassel, Ben M. Brumpton, Martijn A. Spruit, Arnulf Langhammer, Sigurd Steinshamn.

Formal analysis: Øystein Rasch-Halvorsen.

Investigation: Haldor Jenssen.

Methodology: Øystein Rasch-Halvorsen, Erlend Hassel, Ben M. Brumpton, Martijn A. Spruit, Arnulf Langhammer, Sigurd Steinshamn.
Writing – original draft: Øystein Rasch-Halvorsen, Erlend Hassel, Ben M. Brumpton, Haldor Jenssen, Martijn A. Spruit, Arnulf Langhammer, Sigurd Steinshamn.

Writing – review & editing: Øystein Rasch-Halvorsen, Erlend Hassel, Ben M. Brumpton, Haldor Jenssen, Martijn A. Spruit, Arnulf Langhammer, Sigurd Steinshamn.

References

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017; 195(5):557–82. https://doi.org/10.1164/rcm.201701-0218PP PMID: 28128970

2. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J. 2005; 25(1):186–99. https://doi.org/10.1183/09031936.04.00113204 PMID: 15640341

3. Pellegrino R, Brusasco V, Rodarte JR, Babb TG. Expiratory flow limitation and regulation of end-expiratory lung volume during exercise. J Appl Physiol (1985). 1993; 74(5):2552–8. https://doi.org/10.1152/jappl.1993.74.5.2552 PMID: 835591

4. O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(5):770–7. https://doi.org/10.1164/ajrccm.164.5.2012122 PMID: 11549531

5. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171(9):972–7. https://doi.org/10.1164/rcm.200407-855OC PMID: 15665324

6. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003; 167(4):544–9. https://doi.org/10.1164/rccm.200206-583OC PMID: 12446268

7. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006; 119(10 Suppl 1):21–31. https://doi.org/10.1016/j.amjmed.2006.08.004 PMID: 16996896

8. Bauerle O, Younes M. Role of ventilatory response to exercise in determining exercise capacity in COPD. J Appl Physiol (1985). 1995; 79(6):1870–7. https://doi.org/10.1152/jappl.1995.79.6.1870 PMID: 8847246

9. Foglio K, Carone M, Pagani M, Bianchi L, Jones PW, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med. 2000; 94(3):256–63. https://doi.org/10.1053/rmed.1999.0734 PMID: 10783937

10. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002; 20(5):1117–22. https://doi.org/10.1183/09031936.02.00023202 PMID: 12449163

11. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest. 2011; 139(1):52–9. https://doi.org/10.1378/chest.10-0189 PMID: 20522571

12. Vollmer WM, Gislason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009; 34(3):588–97. https://doi.org/10.1183/09031936.0004608 PMID: 19460786

13. Quanjer PH, Ruppel G, Brusasco V, Perez-Padilla R, Fraga CA, Culebras BH, et al. COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. Eur Respir J. 2015; 46(5):1523–4. https://doi.org/10.1183/13993003.01295-2015 PMID: 26521284

14. Pellegrino R, Vieggi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948–68. https://doi.org/10.1183/09031936.05.0035205 PMID: 16264058

15. Augustin IML, Spruit MA, Houben-Wilke S, Franssen FME, Vanfleteren L, Gaffron S, et al. The respiratory physiome: Clustering based on a comprehensive lung function assessment in patients with COPD. PLoS One. 2018; 13(9):e0201593. https://doi.org/10.1371/journal.pone.0201593 PMID: 30208035

16. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182(5):598–604. https://doi.org/10.1164/rcm.200912-1843CC PMID: 20522794
17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40 (6):1324–43. https://doi.org/10.1183/09031936.00080312 PMID: 22743675

18. Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, et al. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017; 50(3). https://doi.org/10.1183/13993003.0010-2017 PMID: 28893868

19. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;165–40. PMID: 8499054

20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26(2):319–38. https://doi.org/10.1183/09031936.05.00034805 PMID: 16055882

21. Campbell SC. A comparison of the maximum voluntary ventilation with the forced expiratory volume in one second: an assessment of subject cooperation. J Occup Med. 1982; 24(7):531–3. PMID: 7119913

22. American Thoracic S, American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167(2):211–77. https://doi.org/10.1164/rccm.167.2.211 PMID: 12524257

23. Pepin V, Saey D, Laviolette L, Maltais F. Exercise capacity in chronic obstructive pulmonary disease: mechanisms of limitation. COPD. 2007; 4(3):195–204. https://doi.org/10.1080/15412550701480489 PMID: 17729063

24. Farkhooy A, Janson C, Arnardottir RH, Malinovschi A, Emtner M, Hedenstrom H. Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD. COPD. 2013; 10 (2):180–5. https://doi.org/10.3109/15412555.2012.734873 PMID: 23547629

25. Paoletti P, De Filippis F, Fraioli F, Cinquanta A, Valli G, Laveneziana P, et al. Cardiopulmonary exercise testing (CPET) in pulmonary emphysema. Respir Physiol Neurobiol. 2011; 179(2–3):167–73. https://doi.org/10.1016/j.resp.2011.07.013 PMID: 21840426

26. Rinaldo RF, Mondoni M, Comandini S, Lombardo P, Vigo B, Terraneo S, et al. The role of phenotype on ventilation and exercise capacity in patients affected by COPD: a retrospective study. Multidiscip Respir Med. 2020; 15(1):476. https://doi.org/10.4081/mrm.2020.476 PMID: 32153779

27. Boutou AK, Shrikrishna D, Tanner RJ, Smith C, Kelly JL, Ward SP, et al. Lung function indices for predicting mortality in COPD. Eur Respir J. 2013; 42(3):616–25. https://doi.org/10.1183/09031936.00146012 PMID: 23349449

28. Poole DC, Jones AM. Measurement of the maximum oxygen uptake Vo2max: Vo2peak is no longer acceptable. J Appl Physiol (1985). 2017; 122(4):997–1002.